°æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå : ºÎ¹®º°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Oral Solid Dosage Contract Manufacturing Market, By Product Type, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1555497
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 365 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

°æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶(Oral Solid Dosage Contract Manufacturing) ½ÃÀå ±Ô¸ð´Â 2023³â 358¾ï 9,718¸¸ ´Þ·¯¿´À¸¸ç, 2024³âºÎÅÍ 2032³â±îÁö CAGR 5.6%·Î ÃßÀÌÇϸç È®´ë µÉ °ÍÀ¸·Î ¿¹»ó

°æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå-½ÃÀå ¿ªÇÐ

Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¹ÙÀÌ¿À »ê¾÷ÀÇ ³ôÀº ¼ö¿ä°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ Àü¸Á

Á¦³×¸¯ ÀǾàǰÀº ¼±¹ß ÀǾàǰ¿¡ ºñÇØ ºñ¿ë È¿°ú°¡ ³ô±â ¶§¹®¿¡ äÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç OSD ¼öŹÁ¦Á¶ ¼­ºñ½º ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰ Á¦Á¶¾÷ü´Â °íǰÁúÀÇ ºñ¿ë È¿À²ÀûÀÎ Á¤Á¦ ¹× ĸ½¶À» »ý»êÇϱ⠶§¹®¿¡ ¼öŹÁ¦Á¶¾÷ü¿¡ ÀÇÁ¸ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¼öŹÁ¦Á¶´Â Á¦Á¶ ½Ã¼³ ¹× ¼³ºñ¿¡ ´ëÇÑ ¼³ºñ ÅõÀÚÀÇ Çʿ伺À» ÁÙÀÓÀ¸·Î½á ºñ¿ë ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÌ È®À强Àº ½ÃÀå¿¡ ´ëÇÑ ¼ö¿ä¿¡ µû¶ó »ý»ê·®À» Á¶Á¤ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ¸Å·ÂÀûÀÔ´Ï´Ù.

Á¦¾àȸ»ç¿Í »ý¸í°øÇÐ ±â¾÷, ƯÈ÷ ½Å¾à °³¹ß¿¡ ÁÖ·ÂÇÏ´Â ±â¾÷ÀÇ È®´ë´Â Á¦Á¶ À§Å¹ ¼­ºñ½ºÀÇ Çʿ伺À» À̲ø¾î ¿Ô½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº Àڻ翡¼­ ´ë±Ô¸ð »ý»êÀ» Çϱâ À§ÇÑ ÀÚ¿ø°ú ¼³ºñ°¡ ºÎÁ·ÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. ¶ÇÇÑ ¾Æ½Ã¾Æ ÅÂÆò¾ç°ú ³²¹Ì µî Áö¿ª¿¡¼­ ÀǾàǰ ½ÃÀåÀÌ ¼ºÀåÇϰí ÀÖ´Â °Íµµ Á¦Á¶ À§Å¹ÀÇ »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÅÈï ½ÃÀå ÁøÃâÀ» ¸ñÇ¥·Î ÇÏ´Â Á¦¾à±â¾÷Àº ±ÔÁ¦¿ä°Ç ¹× À¯Åë¸ÁÀÇ Á¤ºñ¸¦ ÁøÇàÇϱâ À§ÇØ ÇöÁö ¼öŹÁ¦Á¶¾÷ü¿Í Á¦ÈÞÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.

°æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå-ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ® ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È CAGR ¾à 5.6%·Î ¿¬°£ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

Á¦Ç° À¯Çüº°·Î Á¤Á¦°¡ ³ôÀº ºñ¿ë È¿°ú·Î 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸¿©ÁÙ °ÍÀ¸·Î ¿¹»óµÇ¾ú½À´Ï´Ù.

¿ëµµº°·Î´Â ½Å¾à °³¹ß ¼ö¿ä°¡ ³ô±â ¶§¹®¿¡ ÀǾàǰ °³¹ß ºÐ¾ß°¡ 2023³âÀÇ ÁÖ¿ä ¿ëµµ¿´½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â °íÇü Á¦Á¦¡¤Á¦Á¶ ¼ö¿ä°¡ ³ô±â ¶§¹®¿¡ ´ë±â¾÷¿ëÀÌ 2023³âÀÇ ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ¿´½À´Ï´Ù.

Áö¿ªº°·Î´Â ¾Æ½Ã¾Æ ÅÂÆò¾çÀÌ API »ê¾÷ÀÇ »ý»ê·® Áõ°¡·Î 2023³â ¸ÅÃâÀ» À̲ø¾ú½À´Ï´Ù.

°æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå-¼¼ºÐÈ­ ºÐ¼® :

¼¼°è °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ±¸ºÐµË´Ï´Ù.

Á¦Ç° À¯Çü¿¡ µû¶ó Á¤Á¦, ĸ½¶, ºÐ¸», °ú¸³Á¦ µîÀ¸·Î ºÐ·ùµË´Ï´Ù. ½ÃÀåÀ» µ¶Á¡ÇÏ´Â °ÍÀº Á¤Á¦ÀÔ´Ï´Ù. Á¦Á¦È­°¡ ½±°í »ý»êÀÌ ºü¸£´Ù´Â °ÍÀºÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â °ÍÀº ĸ½¶ÀÔ´Ï´Ù.

½ÃÀåÀº ¿ëµµº°·Î ´ÙÀ½ ¹üÁÖ·Î ºÐ·ùµË´Ï´Ù : ÀǾàǰ °³¹ß, ¿ÏÁ¦Ç° Á¦Á¶, ¿ø·á Á¦Á¶, ±âŸ. ÀǾàǰ °³¹ß ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ½Å¾à ¹ß°ßÀ» À§ÇÑ Á¤ºÎÀÇ Áö¿øÃ¥Àº ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î ´ë±â¾÷, Áß¼Ò±â¾÷ µîÀ¸·Î ºÐ·ùµË´Ï´Ù. ´ë±â¾÷ ºÎ¹®Àº ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼öŹÁ¦Á¶ Á¶Á÷°ú Á¦Ç° Çõ½ÅÀÌ ºÎ¹® ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

°æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå-Áö¸®Àû ÅëÂû

Áö¿ªÀûÀ¸·Î, ÀÌ ½ÃÀåÀº ºÏ¹Ì, ³²¹Ì, À¯·´, ¾Æ½Ã¾Æ ÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °¢ Áö¿ªÀ¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ºÏ¹Ì¿¡´Â ¸¹Àº Á¦¾àȸ»ç¿Í ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÌ Á¸ÀçÇϸç, ¿¬±¸°³¹ß°ú Çõ½Å¿¡ ÁÖ·ÂÇϰí ÀÖ´Â °ÍÀÌ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ¶ÇÇÑ Ã·´Ü Á¦Á¶ ±â¼ú°ú È®¸³µÈ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©·Î Ãູ¹Þ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾Æ ÅÂÆò¾çÀº ¼¼°è ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. Á¦Á¶ºñ¿ë ÀúÇÏ, Á¦¾à¾÷°è ¼ºÀå, ÇコÄɾî ÅõÀÚ Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

°æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå-°æÀï ±¸µµ :

°æ±¸ °íÇüÁ¦(OSD) ¼öŹÁ¦Á¶ ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÏ¿© ¼ö¸¹Àº ±â¾÷µéÀÌ ´Ù¾çÇÑ ¼öŹÁ¦Á¶ ¼­ºñ½º¿Í Çõ½ÅÀ» Á¦°øÇÕ´Ï´Ù. °¢ ȸ»ç´Â È¿À²¼º Çâ»ó, ºñ¿ë Àý°¨, Á¦Ç° ǰÁú Çâ»óÀ» À§ÇØ ¿¬¼Ó Á¦Á¶ ¹× °í¼Ó ¾ÐÃà°ú °°Àº °í±Þ Á¦Á¶ ±â¼ú¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷Àº OSD Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ°í ½ÅÁ¦Ç°ÀÇ »ó½Ã¿¡ ´ëÀÀÇϱâ À§ÇØ Á¦Á¶ ½Ã¼³°ú ´É·ÂÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶-ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ¾÷°è ¿¬±¸

Á¦5Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå »óȲ

Á¦7Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå-Á¦Ç° À¯Çüº°

Á¦8Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå-¿ëµµº°

Á¦9Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå-ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå-Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼®-°æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶ »ê¾÷

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Oral Solid Dosage Contract Manufacturing Market size was valued at USD 35,897.18 Million in 2023, expanding at a CAGR of 5.6% from 2024 to 2032.

Oral Solid Dosage (OSD) Contract Manufacturing is the process where pharmaceutical companies outsource the production of solid dosage forms, like tablets, capsules, and powders, to specialized third-party manufacturers. These contract manufacturers handle various stages of production, from formulation development to packaging, ensuring that the products meet required quality and regulatory standards.

Oral Solid Dosage Contract Manufacturing Market- Market Dynamics

Growing demand for generic drugs and high demand from biotech industries are expected to propel market demand

The increasing adoption of generic drugs, due to their cost-effectiveness compared to branded medications, drives demand for OSD contract manufacturing services. Generic drug manufacturers often rely on contract manufacturers to produce high-quality, cost-effective tablets and capsules. Contract manufacturing offers cost advantages by reducing the need for capital investment in manufacturing facilities and equipment. This scalability is attractive to companies looking to adjust production volumes based on market demand without significant upfront investment.

The expansion of pharmaceutical and biotech companies, especially those focused on new drug development, leads to the need for contract manufacturing services. These companies often lack the resources or facilities to handle large-scale production in-house. In addition, growing pharmaceutical markets in regions such as Asia-Pacific and Latin America create new opportunities for contract manufacturing. Pharmaceutical companies seeking to enter these emerging markets often partner with local contract manufacturers to navigate regulatory requirements and distribution network capabilities.

Oral Solid Dosage Contract Manufacturing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.6% over the forecast period (2024-2032)

Based on Product Type segmentation, the tablets segment was predicted to show maximum market share in the year 2023, owing to their high cost-effectiveness.

Based on Application segmentation, the drug product development segment was the leading application in 2023, owing to high demand from novel drug developments.

Based on End User segmentation, the large companies' segment was the leading End User in 2023, owing to high demand for solid dose formulations & manufacturing.

Based on region, Asia Pacific was the leading revenue generator in 2023, due to the growing production in API industries.

Oral Solid Dosage Contract Manufacturing Market- Segmentation Analysis:

The Global Oral Solid Dosage Contract Manufacturing Market is segmented based on Product Type, Application, End User, and Region.

The market is divided into three categories based on Product Type: tablets, capsules, powder, granules, and others. The tablet segment dominates the market. Easy formulation and fast production are increasing the segment growth. The capsules segment is expected to grow at the fastest rate over the forecast period.

The market is divided into four categories based on Application: drug product development, fill finish product manufacturing, API manufacturing, and others. The drug product development segment dominates the market. Supportive government initiatives for novel drug discoveries are boosting segment growth.

The market is divided into three categories based on End Users: large companies, small & medium sized companies, and others. The large companies segment dominates the market and is expected to maintain its high dominance during the forecast period. Contract manufacturing organizations and product innovations are contributing to segment demand.

Oral Solid Dosage Contract Manufacturing Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America has the presence of many pharmaceutical and biotech companies, along with a strong emphasis on R&D and innovation, which drives demand. The region also benefits from advanced manufacturing technologies and a well-established regulatory framework. Asia Pacific dominates the global market. Lower production costs, a growing pharmaceutical industry, and increasing investment in healthcare drive market growth.

Oral Solid Dosage Contract Manufacturing Market- Competitive Landscape:

The Oral Solid Dosage (OSD) Contract Manufacturing market is competitive, with numerous players offering a range of contract manufacturing services and innovations. Companies are investing significantly in advanced manufacturing technologies, such as continuous manufacturing and high-speed compression, to improve efficiency, reduce costs, and enhance product quality. Key players are expanding their manufacturing facilities and capabilities to meet the growing demand for OSD products and to accommodate new product launches.

Recent Developments:

In July 2023, Aenova Group and Galvita formed a strategic partnership to enhance oral dosage forms' formulation, development, and production.

In April 2023, Aenova invested around USD 22 million to expand its high-volume solids site in Tittmoning, U.S., resulting in increased capacity.

In March 2023, Lonza completed the construction of clinical & drug product manufacturing in Visp, Switzerland.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET KEY PLAYERS

GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, BY END USER- MARKET ANALYSIS, 2019-2032

GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Oral Solid Dosage Contract Manufacturing Market Overview

2. Executive Summary

3. Oral Solid Dosage Contract Manufacturing Key Market Trends

4. Oral Solid Dosage Contract Manufacturing Industry Study

5. Oral Solid Dosage Contract Manufacturing Market: COVID-19 Impact Analysis

6. Oral Solid Dosage Contract Manufacturing Market Landscape

7. Oral Solid Dosage Contract Manufacturing Market - By Product Type

8. Oral Solid Dosage Contract Manufacturing Market - By Application

9. Oral Solid Dosage Contract Manufacturing Market - By End User

10. Oral Solid Dosage Contract Manufacturing Market- By Geography

11. Key Vendor Analysis- Oral Solid Dosage Contract Manufacturing Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â